Outcomes in women with a history of gestational diabetes. Screening and prevention of type 2 diabetes. Literature review

被引:56
|
作者
Verier-Mine, O. [1 ]
机构
[1] Hop Jean Bernard, Serv Endocrinol Diabetol Obesite, F-59322 Valenciennes, France
关键词
gestational diabetes mellitus; screening; type; 2; diabetes; cardiovascular disease; metabolic syndrome; review; LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL FUNCTION; METABOLIC SYNDROME; FOLLOW-UP; CARDIOVASCULAR-DISEASE; RISK-FACTORS; INCREASING INCIDENCE; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY;
D O I
10.1016/j.diabet.2010.11.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Women with a history of gestational diabetes mellitus (GDM) are characterized by a high risk of type 2 diabetes mellitus (T2DM) (x 7), metabolic syndrome (x 2 to 5) and cardiovascular diseases (x 1,7). Women with lesser degrees of glucose intolerance share the same risks. T2DM may occur from post-partum (5 to 14%) to several years later, up to 25 years. Some factors associated with T2DM are identified: obesity, early diagnosis of GDM before 24 weeks gestation, high pregnancy OGTT blood glucose or insulin-therapy during GDM. Screening for T2DM only with fasting glucose provides less sensibility than with OGTT; HbA(1c) may supplant these dosages. The recurrence rate of GDM is between 30 and 84%, non-white ethnicity and insulinotherapy during GDM being the best proven predictors. High risk women need repeated life-long screenings for glycaemic abnormalities, or when another pregnancy is planned. Among obese women with history of GDM who show minor glycoregulation disturbances, modifications of lifestyle in intensive programs or metformin halve the risk of DT2. However, studies analysing practices show low adhesion to screening; without an intensive program, few women implement lifestyle modifications. These intensive programs should be implemented and proposed to high-risk women. Their therapeutic education should also include prevention of cardiovascular risk factors. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:595 / 616
页数:22
相关论文
共 50 条
  • [31] Agents in development for type 2 diabetes.
    Jarvis B.
    Elkinson S.
    [J]. Drugs in R & D, 1999, 2 (2) : 95 - 99
  • [32] Mortality in people with Type 2 diabetes.
    Lawrenson, R
    Mulnier, H
    Raleigh, V
    [J]. DIABETOLOGIA, 2003, 46 : A77 - A77
  • [33] Nephropathy in patients with type 2 diabetes.
    Remuzzi, G
    Schieppati, A
    Ruggenenti, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15): : 1145 - 1151
  • [34] Arterial hypertension and type 2 diabetes.
    Louda, F.
    Addi, H.
    Hallab, L.
    Chadli, A.
    Elghomari, H.
    Farouqi, A.
    [J]. DIABETES & METABOLISM, 2010, 36 : A53 - A54
  • [35] Insulin therapy in type 2 diabetes.
    Ametov, A
    Topchiashvili, V
    [J]. DIABETOLOGIA, 1997, 40 : 1685 - 1685
  • [36] Cardiovascular fitness and type 2 diabetes.
    Mullooly C.
    [J]. Current Diabetes Reports, 2002, 2 (5) : 441 - 447
  • [37] Protein diet in type 2 diabetes. No
    Pelaz-Berdullas, Laura
    Luis Calle-Pascual, Alfonso
    [J]. AVANCES EN DIABETOLOGIA, 2012, 28 (01): : 27 - 31
  • [38] Primary prevention, aspirin and diabetes.
    Balaguer Vintro, Ignacio
    [J]. REVISTA ESPANOLA DE SALUD PUBLICA, 2006, 80 (06): : 609 - 612
  • [39] Nephropathy in type 2 diabetes. Reply
    Ritz, E
    Orth, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (06): : 442 - 442
  • [40] Glomerular ultrastructure in type 2 diabetes.
    Fioretto, P
    Mauer, M
    Barzon, I
    Dalla Vestra, M
    Bortoloso, E
    Saller, A
    Nosadini, R
    Crepaldi, G
    [J]. DIABETOLOGIA, 1999, 42 : A268 - A268